Search

Your search keyword '"D'Offizi, Gianpiero"' showing total 474 results

Search Constraints

Start Over You searched for: Author "D'Offizi, Gianpiero" Remove constraint Author: "D'Offizi, Gianpiero"
474 results on '"D'Offizi, Gianpiero"'

Search Results

2. Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination

4. Epidemiology of ventilator-associated pneumonia in ICU COVID-19 patients: an alarming high rate of multidrug-resistant bacteria

5. Proteomic analysis identifies a signature of disease severity in the plasma of COVID-19 pneumonia patients associated to neutrophil, platelet and complement activation

7. Role of testosterone in SARS-CoV-2 infection: A key pathogenic factor and a biomarker for severe pneumonia

8. Risk and predictive factors of prolonged viral RNA shedding in upper respiratory specimens in a large cohort of COVID-19 patients admitted to an Italian reference hospital

9. RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies

10. Torquetenovirus Loads in Peripheral Blood Predict Both the Humoral and Cell-Mediated Responses to SARS-CoV-2 Elicited by the mRNA Vaccine in Liver Transplant Recipients

14. Early expansion of myeloid-derived suppressor cells inhibits SARS-CoV-2 specific T-cell response and may predict fatal COVID-19 outcome

16. Evolution of SARS‐CoV‐2 variants of concern over a period of Delta and Omicron cocirculation, among patients hospitalized for COVID‐19 in an Italian reference hospital: Impact on clinical outcomes

18. Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination

19. Third dose of SARS‐CoV2 mRNA vaccination produces robust persistent cellular and humoral immune responses in liver transplant recipients

21. Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel

23. Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program

24. Forecasting the long‐term impact of COVID‐19 on hepatitis C elimination plans in Italy: A mathematical modelling approach.

25. "Real world" efficacy of bulevirtide in HBV/HDV‐related cirrhosis including people living with HIV: Results from the compassionate use programme at INMI Spallanzani in Rome, Italy.

26. Virological and Clinical Outcomes of Patients with Hdv-Related Compensated Cirrhosis Treated with Bulevirtide Monotherapy: The Retrospective Multicenter European Study (Save-D)

27. Repeated Cycles of Recombinant Human Interleukin 7 in HIV-Infected Patients With Low CD4 T-Cell Reconstitution on Antiretroviral Therapy; Results of 2 Phase II Multicenter Studies

28. Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post‐transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study

30. Aero-Medical Evacuation during SARS-CoV-2 Pandemic: Extraordinary Measure or Emerging Treatment Option?

35. Reliability and Clinical Relevance of the HIV-1 Drug Resistance Test in Patients With Low Viremia Levels

36. Impact of new DAA therapy on real clinical practice: a multicenter region-wide cohort study

37. Timing and outcomes of noninvasive ventilation in 307 ARDS COVID-19 patients: an observational study in an Italian third level COVID-19 hospital

39. Additional file 1 of Proteomic analysis identifies a signature of disease severity in the plasma of COVID-19 pneumonia patients associated to neutrophil, platelet and complement activation

40. Aero-Medical Evacuation during SARS-CoV-2 Pandemic: Extraordinary Measure or Emerging Treatment Option?

41. Characteristics and Outcomes of COVID-19-Related Hospitalization among PLWH

42. In vitro Evaluation of Antiviral Efficacy of a Standardized Hydroalcoholic Extract of Poplar Type Propolis Against SARS-CoV-2

44. High prevalence of asymptomatic SARS-CoV-2 infection in a cohort of Liver Transplant Recipients in Central Italy

45. Fibrogenic signals persist in DAA-treated HCV patients after sustained virological response

46. Coordinated cellular and humoral immune responses after two‐dose SARS‐CoV2 mRNA vaccination in liver transplant recipients

47. Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Combination Therapy in Patients With Coronavirus Disease 2019 and Primary Antibody Deficiency

Catalog

Books, media, physical & digital resources